Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients A Pragmatic Trial (EVOLUTION).

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Psoriatic Arthritis
  • Age: Between 18 Year(s) - 80 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Psoriatic arthritis
    2. Active psoriatic arthritis defined by the presence of at least 2 swollen joints OR 1 swollen joint and 1 site of active enthesitis OR active dactylitis involving 2 joints
    3. At least one active psoriasis p

You may not be eligible for this study if the following are true:

    1. Prior exposure to golimumab or another non-TNFi biologic (IL12/23i, JAKi, IL17i, or an IL23i)
    2. An adverse event that precludes use of another TNFi (development of drug-induced SLE, allergic reaction, serious infection, heart failure s


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.